F-star Therapeutics, Inc.
FSTX · NASDAQ
9/30/2022 | 6/30/2022 | 3/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | -85.4% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | – | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | $0 |
| % Margin | -1,580.4% | – | -452.1% | 20.4% |
| Net Income | -$0 | -$0 | -$0 | $0 |
| % Margin | -1,641.5% | – | -476.1% | 27.1% |
| EPS Diluted | -0.84 | -0.89 | -0.58 | 0.23 |
| % Growth | 5.6% | -53.4% | -352.2% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | $0 |
| Capital Expenditures | -$0 | -$0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | $0 |